Key Factors for Choosing the Right CDMO
In a guest column Kevin Wall, principal consultant and owner of Cincero Consulting, emphasizes the critical importance of selecting the […]
Key Factors for Choosing the Right CDMO Read Post »
In a guest column Kevin Wall, principal consultant and owner of Cincero Consulting, emphasizes the critical importance of selecting the […]
Key Factors for Choosing the Right CDMO Read Post »
Loss of exclusivity (LOE) doesn’t have to spell doom for branded drug revenue streams. In the face of impending patent
A recent paper in Expert Opinion on Biological Therapy studies failed fillings for biosimilar drugs. Over the past three decades, biotherapeutics
Unsuccessful Regulatory Filings for Biosimilar Approval: A Comprehensive Review Read Post »
DrugPatentWatch now offers single drug reports for purchase on Amazon. These reports provide valuable insights and information about specific drugs.
Drug Patent Reports now available on Amazon Read Post »
A recent paper published in the journal “Intelligent Medicine” article discusses various aspects of using AI and machine learning in
Artificial Intelligence and Machine Learning in Drug Discovery and Development Read Post »
A recent study explores the landscape of authorized generics in the United States pharmaceutical market. Authorized generics are brand-name drugs
Prevalence and timing of authorized generics in the US market Read Post »
A recent update from Foley & Lardner attorney Courtenay C. Brinckerhoff discusses trends in Inter Partes Review (IPR) and Post Grant
Insights into Shifting Dynamics: Orange Book and Biologic PTAB Trends Read Post »
In a recent Insight article published by Global Competition Review, legal experts from Lowenstein Sandler LLP delve into the status
In the world of prescription drugs, brand-name manufacturers have employed various strategies to maintain revenue streams in the face of
Get fresh news and insights, drug patent expirations & more…